Al Mare Perearstikeskus OU

At Al Mare Family Doctors Centre in Tallinn, clinical research focuses on vaccine studies for common infectious diseases, especially pneumococcal disease, influenza, varicella, and cytomegalovirus infection. These trials are designed to assess how well new or updated vaccines stimulate immune responses and to monitor their safety in healthy participants across different age groups.

• Pneumococcal vaccination research in infants, children, and adolescents, comparing immune responses to newer conjugate vaccine options.
• Influenza studies in older adults, evaluating whether a high-dose vaccine can improve protection against seasonal flu.
• Varicella and MMR vaccine studies in young children, looking at immune response and safety when given by different routes.
• Cytomegalovirus vaccine research in healthy adults, aiming to prevent primary infection and assess tolerability.

Overall, the site contributes to immunization research that helps refine preventive care for both children and adults, with a strong emphasis on measuring effectiveness and reactogenicity.

A major part of the trial portfolio at Al Mare Perearstikeskus OU is devoted to pneumococcal conjugate vaccines. These studies explore whether newer vaccine formulations can produce immune responses that are at least as strong as existing options, while also examining broader protection against additional serotypes.

• Evaluation of immune response in healthy infants receiving a 21-valent pneumococcal vaccine.
• Catch-up vaccination studies in toddlers, children, and adolescents to understand immune coverage across age groups.
• Comparison of antibody levels and functional immune activity to support vaccine effectiveness.

This work supports the ongoing development of improved pneumococcal immunization strategies for pediatric populations.

The site also participates in research on seasonal influenza vaccination for adults aged 60 years and older. The main goal is to determine whether a high-dose influenza vaccine can generate a stronger immune response than an established comparator, helping improve protection in a group that is more vulnerable to flu-related complications.

• Influenza immunization studies in older adults.
• Assessment of antibody response and vaccine performance.
• Research aimed at strengthening preventive care for age-related risk.

These trials contribute to better understanding of how to optimize flu prevention in an aging population.

Another important area of study involves varicella and measles, mumps, and rubella vaccination in young children. The research is centered on whether investigational and routine vaccines can be administered safely while still producing a reliable immune response.

• Studies of chickenpox vaccine safety and immune response in healthy children.
• Research on combined MMR vaccination alongside other childhood immunizations.
• Evaluation of tolerability and immunogenicity in early childhood.

This line of research supports practical improvements in routine pediatric vaccination and helps inform how vaccines can be used effectively in everyday care.

The clinical trial portfolio at Al Mare Perearstikeskus OU also includes research on cytomegalovirus, a viral infection of particular concern in susceptible adults. These studies aim to test whether a new vaccine candidate can help prevent primary infection while maintaining an acceptable safety profile.

• Prevention-focused research in CMV-seronegative female participants.
• Evaluation of vaccine safety and immune response.
• Work aimed at advancing viral infection prevention through vaccination.

This study area reflects the site’s broader emphasis on infectious disease prevention through innovative vaccine research.